Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,824.66
(
0.62%
)
US TECH 100
24,421.20
(
0.06%
)
Dow Jones
48,185.80
(
0.58%
)
Brent Oil
94.07
(
-0.41%
)
Bitcoin
71,756.02
(
-0.04%
)
News Focus
News Focus
Post# of 257375
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: seschm post# 210383

Monday, 04/03/2017 1:47:08 PM

Monday, April 03, 2017 1:47:08 PM

Post# of 257375
>> In the AML cohort, one patient with minimal residual disease (consisting of 0.7% abnormal blasts at baseline) obtained a complete molecular remission after 4 infusions of TTI-621. A second marrow analysis at week 8 confirmed a complete molecular remission, the patient continues to tolerate weekly infusions of TTI-621 and remains in continued remission for 15+ weeks.

This is very good news.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today